Should You Be Adding Shanghai Allist Pharmaceuticals (SHSE:688578) To Your Watchlist Today?
Should You Be Adding Shanghai Allist Pharmaceuticals (SHSE:688578) To Your Watchlist Today?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. Unfortunately, these high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson. Loss making companies can act like a sponge for capital - so investors should be cautious that they're not throwing good money after bad.
即使这意味着购买无任何收入,更不用说利润的“故事股”,投资者常常被寻找“下一个大事件”的想法引导。不幸的是,这些高风险投资往往几乎没有可能获得回报,许多投资者付出代价才能吸取教训。亏损的公司会像资本的海绵一样 - 因此投资者应该谨慎,不要在徒劳无功的投资后投入好钱去赚坏钱。
If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Shanghai Allist Pharmaceuticals (SHSE:688578). Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business.
如果这种类型的公司不是你的菜,你喜欢那些能够产生营业收入甚至盈利的公司,那么你可能对上海阿里斯制药(SHSE:688578)感兴趣。现在并不是说这家公司提供了最好的投资机会,但盈利能力是业务成功的关键组成部分。
Shanghai Allist Pharmaceuticals' Improving Profits
上海阿里斯制药的利润改善
Strong earnings per share (EPS) results are an indicator of a company achieving solid profits, which investors look upon favourably and so the share price tends to reflect great EPS performance. So a growing EPS generally brings attention to a company in the eyes of prospective investors. It is awe-striking that Shanghai Allist Pharmaceuticals' EPS went from CN¥0.69 to CN¥2.43 in just one year. While it's difficult to sustain growth at that level, it bodes well for the company's outlook for the future. This could point to the business hitting a point of inflection.
强劲的每股收益(EPS)结果是公司实现稳健盈利的指标,投资者对此持欢迎态度,因此股价往往会反映出出色的EPS表现。因此,不断增长的EPS通常会引起潜在投资者的关注。令人惊叹的是,上海阿里斯制药的EPS仅在一年内从0.69元人民币增长到2.43元人民币。虽然很难保持那个增长水平,但对公司未来的前景是一个好兆头。这可能表明业务达到了一个拐点。
Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. Shanghai Allist Pharmaceuticals shareholders can take confidence from the fact that EBIT margins are up from 18% to 37%, and revenue is growing. Ticking those two boxes is a good sign of growth, in our book.
仔细考虑营收增长和利润之前的利息和税前利润(EBIT)利润率可以帮助判断最近利润增长的可持续性。上海阿里斯制药股东可以从EBIT利润率从18%增长到37%以及营收增长中获得信心。这两个方面表现良好是我们看到的增长的好迹象。
The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers.
下面的表格显示了公司的营收和净利润如何随着时间的推移的变化。点击图表可以查看准确的数字。
You don't drive with your eyes on the rear-view mirror, so you might be more interested in this free report showing analyst forecasts for Shanghai Allist Pharmaceuticals' future profits.
你不会开车时只盯着后视镜,因此您可能会对这份显示上海爱力斯制药未来盈利预测的免费报告更感兴趣。
Are Shanghai Allist Pharmaceuticals Insiders Aligned With All Shareholders?
上海爱力斯制药内部人士与所有股东保持一致吗?
It's a necessity that company leaders act in the best interest of shareholders and so insider investment always comes as a reassurance to the market. So it is good to see that Shanghai Allist Pharmaceuticals insiders have a significant amount of capital invested in the stock. Indeed, they have a considerable amount of wealth invested in it, currently valued at CN¥2.5b. Investors will appreciate management having this amount of skin in the game as it shows their commitment to the company's future.
公司领导者必须为股东的最大利益行事,因此内部投资始终是市场的一种安抚。因此,看到上海爱力斯制药内部人士在该股票中投入了大量资金是件好事。实际上,他们在其中投入了相当可观的财富,目前价值为25亿人民币。投资者将感激管理层在游戏中拥有这么大的利益,因为这显示了他们对公司未来的承诺。
Should You Add Shanghai Allist Pharmaceuticals To Your Watchlist?
您应该将上海爱力斯制药添加到您的自选中吗?
Shanghai Allist Pharmaceuticals' earnings per share have been soaring, with growth rates sky high. That EPS growth certainly is attention grabbing, and the large insider ownership only serves to further stoke our interest. The hope is, of course, that the strong growth marks a fundamental improvement in the business economics. So based on this quick analysis, we do think it's worth considering Shanghai Allist Pharmaceuticals for a spot on your watchlist. What about risks? Every company has them, and we've spotted 2 warning signs for Shanghai Allist Pharmaceuticals you should know about.
上海爱力斯制药的每股收益一直在飙升,增长率高得令人瞩目。这种EPS增长确实引人注目,而巨大的内部持股权只会进一步激发我们的兴趣。当然,希望是,强劲的增长标志着业务经济方面的根本改善。因此,基于这一快速分析,我们认为值得考虑将上海爱力斯制药列入您的自选。风险呢?每个公司都会有,我们已经发现了2个上海爱力斯制药的警示信号,您应该知道。
While opting for stocks without growing earnings and absent insider buying can yield results, for investors valuing these key metrics, here is a carefully selected list of companies in CN with promising growth potential and insider confidence.
虽然不选取增长收益和缺少内部人买入的股票可能会产生效果,但是对于重视这些关键指标的投资者,这里是一份精心挑选的具有巨大增长潜力和内部人信心的CN公司列表。
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
请注意,本文讨论的内部交易是指在相关司法管辖区中报告的交易。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。